Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

Naïve CD8+ T cells can differentiate into effector (Teff), memory (Tmem) or exhausted (Tex)
T cells. These developmental pathways are associated with distinct transcriptional and …

Clustered regularly interspaced short palindromic repeats (CRISPR) system provides
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …

Chronic antigen stimulation during viral infections and cancer can lead to T cell exhaustion,
which is characterized by reduced effector function and proliferation, and the expression of …

Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …

The metabolic state represents a major hurdle for an effective adoptive T cell therapy (ACT).
Indeed, specific lipids can harm CD8+ T cell (CTL) mitochondrial integrity, leading to …